BACKGROUND: Pseudomonas aeruginosa is a key respiratory pathogen in people with cystic fibrosis (CF). Due to its association with lung disease progression, initial detection of P. aeruginosa in CF respiratory cultures usually results in antibiotic treatment with the goal of eradication. Pseudomonas aeruginosa exhibits many different phenotypes in vitro that could serve as useful prognostic markers, but the relative relationships between these phenotypes and failure to eradicate P. aeruginosa have not been well characterized. METHODS: We measured 22 easily assayed in vitro phenotypes among the baseline P. aeruginosa isolates collected from 194 participants in the 18-month EPIC clinical trial, which assessed outcomes after antibiotic eradication therapy for newly identified P. aeruginosa. We then evaluated the associations between these baseline isolate phenotypes and subsequent outcomes during the trial, including failure to eradicate after antipseudomonal therapy, emergence of mucoidy, and occurrence of an exacerbation. RESULTS: Baseline P. aeruginosa isolates frequently exhibited phenotypes thought to represent chronic adaptation, including mucoidy. Wrinkly colony surface and irregular colony edges were both associated with increased risk of eradication failure (hazard ratios [95% confidence intervals], 1.99 [1.03-3.83] and 2.14 [1.32-3.47], respectively). Phenotypes reflecting defective quorum sensing were significantly associated with subsequent mucoidy, but no phenotype was significantly associated with subsequent exacerbations during the trial. CONCLUSIONS: Pseudomonas aeruginosa phenotypes commonly considered to reflect chronic adaptation were observed frequently among isolates at early detection. We found that 2 easily assayed colony phenotypes were associated with failure to eradicate after antipseudomonal therapy, both of which have been previously associated with altered biofilm formation and defective quorum sensing.
BACKGROUND:Pseudomonas aeruginosa is a key respiratory pathogen in people with cystic fibrosis (CF). Due to its association with lung disease progression, initial detection of P. aeruginosa in CF respiratory cultures usually results in antibiotic treatment with the goal of eradication. Pseudomonas aeruginosa exhibits many different phenotypes in vitro that could serve as useful prognostic markers, but the relative relationships between these phenotypes and failure to eradicate P. aeruginosa have not been well characterized. METHODS: We measured 22 easily assayed in vitro phenotypes among the baseline P. aeruginosa isolates collected from 194 participants in the 18-month EPIC clinical trial, which assessed outcomes after antibiotic eradication therapy for newly identified P. aeruginosa. We then evaluated the associations between these baseline isolate phenotypes and subsequent outcomes during the trial, including failure to eradicate after antipseudomonal therapy, emergence of mucoidy, and occurrence of an exacerbation. RESULTS: Baseline P. aeruginosa isolates frequently exhibited phenotypes thought to represent chronic adaptation, including mucoidy. Wrinkly colony surface and irregular colony edges were both associated with increased risk of eradication failure (hazard ratios [95% confidence intervals], 1.99 [1.03-3.83] and 2.14 [1.32-3.47], respectively). Phenotypes reflecting defective quorum sensing were significantly associated with subsequent mucoidy, but no phenotype was significantly associated with subsequent exacerbations during the trial. CONCLUSIONS:Pseudomonas aeruginosa phenotypes commonly considered to reflect chronic adaptation were observed frequently among isolates at early detection. We found that 2 easily assayed colony phenotypes were associated with failure to eradicate after antipseudomonal therapy, both of which have been previously associated with altered biofilm formation and defective quorum sensing.
Authors: M Rosenfeld; J Emerson; F Accurso; D Armstrong; R Castile; K Grimwood; P Hiatt; K McCoy; S McNamara; B Ramsey; J Wagener Journal: Pediatr Pulmonol Date: 1999-11
Authors: David A D'Argenio; Manhong Wu; Lucas R Hoffman; Hemantha D Kulasekara; Eric Déziel; Eric E Smith; Hai Nguyen; Robert K Ernst; Theodore J Larson Freeman; David H Spencer; Mitchell Brittnacher; Hillary S Hayden; Sara Selgrade; Mikkel Klausen; David R Goodlett; Jane L Burns; Bonnie W Ramsey; Samuel I Miller Journal: Mol Microbiol Date: 2007-04 Impact factor: 3.501
Authors: Lucas R Hoffman; Hemantha D Kulasekara; Julia Emerson; Laura S Houston; Jane L Burns; Bonnie W Ramsey; Samuel I Miller Journal: J Cyst Fibros Date: 2008-10-29 Impact factor: 5.482
Authors: Lucas R Hoffman; Anthony R Richardson; Laura S Houston; Hemantha D Kulasekara; Willm Martens-Habbena; Mikkel Klausen; Jane L Burns; David A Stahl; Daniel J Hassett; Ferric C Fang; Samuel I Miller Journal: PLoS Pathog Date: 2010-01-08 Impact factor: 6.823
Authors: Gregory B Whitfield; Lindsey S Marmont; Alex Ostaszewski; Jacquelyn D Rich; John C Whitney; Matthew R Parsek; Joe J Harrison; P Lynne Howell Journal: J Bacteriol Date: 2020-03-26 Impact factor: 3.490
Authors: Alex H Gifford; Sven D Willger; Emily L Dolben; Lisa A Moulton; Dana B Dorman; Heather Bean; Jane E Hill; Thomas H Hampton; Alix Ashare; Deborah A Hogan Journal: Infect Immun Date: 2016-09-19 Impact factor: 3.441
Authors: Ruiyi Chen; Eric Déziel; Marie-Christine Groleau; Amy L Schaefer; E Peter Greenberg Journal: Proc Natl Acad Sci U S A Date: 2019-03-07 Impact factor: 11.205
Authors: Rajesh Anand; Richard B Moss; Gabriele Sass; Niaz Banaei; Karl V Clemons; Marife Martinez; David A Stevens Journal: Mycopathologia Date: 2017-08-07 Impact factor: 2.574
Authors: Henrik Almblad; Joe J Harrison; Morten Rybtke; Julie Groizeleau; Michael Givskov; Matthew R Parsek; Tim Tolker-Nielsen Journal: J Bacteriol Date: 2015-04-20 Impact factor: 3.490
Authors: David Williams; Benjamin Evans; Sam Haldenby; Martin J Walshaw; Michael A Brockhurst; Craig Winstanley; Steve Paterson Journal: Am J Respir Crit Care Med Date: 2015-04-01 Impact factor: 21.405
Authors: Daniel J Wolter; Alison Scott; Catherine R Armbruster; Dale Whittington; John S Edgar; Xuan Qin; Anne Marie Buccat; Sharon McNamara; Marcella Blackledge; Adam Waalkes; Stephen J Salipante; Robert K Ernst; Lucas R Hoffman Journal: J Antimicrob Chemother Date: 2021-02-11 Impact factor: 5.790
Authors: Nicole Mayer-Hamblett; Margaret Rosenfeld; Ronald L Gibson; Bonnie W Ramsey; Hemantha D Kulasekara; George Z Retsch-Bogart; Wayne Morgan; Daniel J Wolter; Christopher E Pope; Laura S Houston; Bridget R Kulasekara; Umer Khan; Jane L Burns; Samuel I Miller; Lucas R Hoffman Journal: Am J Respir Crit Care Med Date: 2014-08-01 Impact factor: 21.405